Open company graph database — free web & API
Login

Oncoris BioPharma Inc.

オンコリスバイオファーマ株式会社
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
35
Related companies
10
§01

Basic information

BASIC
Head office
4-1-28 Toranomon, Toranomon Towers Office, Minato-ku, Tokyo, 105-0001
Chief executive
Yasuo Urata
Capital
5,108,000,000 JPY (51 100 millionJPY)
Employees (non-consolidated)
35 people
Employees (consolidated)
Start date
2004-03-18
End date
§02

Websites

1 DOMAINS
§03

Business

2
Research, development, manufacturing, sales, and import/export of tumor-killing viruses.Research, development, manufacturing, sales, and import/export of pharmaceuticals and cancer diagnostic tests.
§04

Related companies

10 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
OPA Therapeutics Inc.
Group Subsidiary
Oncolys USA Inc.
Group Subsidiary
Oncolys USA, Inc.
Group
Medigen Biotechnology Corp.
Group
Astellas Pharma Inc.
Group
Fujifilm Toyama Chemical Co., Ltd.
Group
Mizuho Bank, Ltd.
Bank
Sumitomo Mitsui Banking Corporation
Bank
Mitsubishi UFJ Bank Ltd.
Bank
Japan Finance Corporation
Bank
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

125 EVENTS

Established Oncoris BioPharma Inc. in Minato-ku, Tokyo, with the purpose of researching and developing tumor-lysis viruses and molecular-targeted anti-tumor drugs.Sources

Incorporated Oncolys BioPharma Inc. in Minato-ku, Tokyo for the research and development of oncolytic viruses and molecular targeted anti-cancer drugsSources

OBP-401 was selected for the NEDO (New Energy and Industrial Technology Development Organization) 2005 (Heisei 17) Molecular Imaging Device Research and Development Project / Malignant Tumor Treatment Support Molecular Imaging Device R&D Project grant.Sources

Obtained a grant from NEDO (New Energy and Industrial Technology Development Organization) for research on OBP-401 (TelomeScan) entitled 'Molecule Imaging Device Research and Development Project/Malignant Tumor Treatment Support Molecule Imaging Device Research and Development Project'Sources

Submitted an IND (Investigational New Drug) application for OBP-301 to the U.S. Food and Drug Administration (FDA).Sources

Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-301 (Telomelysin)Sources

Entered an exclusive worldwide licensing agreement with Yale University (USA) for a novel HIV treatment drug and began research and development as OBP-601 (Censavudine).Sources

Concluded a worldwide Exclusive License Agreement with Yale University (U.S.A.) on a new HIV drug, OBP-601(Censavudine) and started research and development on itSources

Moved headquarters to Aoba Building, 3-3 Roppongi, Minato-ku, Tokyo.Sources

Established the Kyoto Research Center in Kyoto City, Kyoto Prefecture, and obtained a Japanese domestic patent (No. 3867968) for OBP-301.Sources

Initiated Phase 1 clinical trials of OBP-301 in the United States.Sources

Established Kyoto Research Center in Kyoto-city, Kyoto Japan Patent 3867968 of OBP-301 (Telomelysin) was issued.Sources

Started Phase 1 clinical trial in the U.S. for TelomelysinSources

Received the 5th Japan Bio-Venture Award Minister of Education, Culture, Sports, Science and Technology Prize (sponsored by Fuji Sankei Business AI).Sources

Received the Grand Prix of the 5th Japan Bio-Venture Award (sponsored by FujiSankei Business i)Sources

Relocated the Kyoto Research Center to Kobe City, Hyogo Prefecture, becoming the Kobe Research Center.Sources

Moved Kyoto Research Center to Kobe-city, Kobe, and named Kobe Research CenterSources

Signed a strategic partnership agreement with Medigen Biotechnology Corp. (Taiwan) regarding OBP-301 and submitted an IND application for OBP-601 (Censavudine) to the U.S. FDA.Sources

Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin) Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine)Sources

Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin)Sources

Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine)Sources

Started Phase 1a clinical trials of OBP-601 (Censavudine) in the United States.Sources

Started Phase 1a clinical trial in the U.S. for OBP-601(Censavudine)Sources

Applied for approval from the French Agency for the Safety of Health Products (AFSSAPS) to conduct Phase 1b/2a clinical trials of OBP-601 (Censavudine).Sources

Filed an application to start Phase 1b/2a clinical trial with French National Agency for the Safety of Health Products (AFSSAPS) for OBP-601(Censavudine)Sources

Commenced Phase 1b/2a clinical trials of OBP-601 (Censavudine) in France.Sources

Started Phase 1b/2a clinical trial in France for OBP-601(Censavudine)Sources

U.S. patent No. 7,589,078 for OBP-601 (Censavudine) was granted.Sources

U.S. Patent 7,589,078 of OBP-601(Censavudine) was issued.Sources

Signed an exclusive worldwide licensing agreement with Astellas Pharma Inc. for a novel molecular-targeted anticancer drug and began research and development as OBP-801.Sources

Concluded a worldwide exclusive license agreement with Astellas Pharma Inc. on a novel molecular targeting anti-cancer drug, and started research and development of OBP-801Sources

OBP-401 was selected for the NEDO (New Energy and Industrial Technology Development Organization) 2010 (Heisei 22) Innovation Utilization Development Grant.Sources

Obtained a grant from NEDO for OBP-401 (TelomeScan) as Innovation Promotion Program for fiscal 2010Sources

Signed an exclusive worldwide licensing agreement with the National Institute of Advanced Industrial Science and Technology (AIST) for the novel diagnostic test OBP-1101 and began research and development.Sources

Concluded an exclusive worldwide license agreement with National Institute of Biomedical Innovation for OBP-1101 (TelomeScan F35) and started research and development of OBP-1101 (TelomeScan F35)Sources

Received the 2011 (Heisei 23) Deals of Distinction Award in the Industry-Government-Academia Collaboration category for the licensing of OBP-601 (Censavudine) at the annual meeting of the Licensing Executives Society of the United States and Canada.Sources

Started Phase 2b clinical trial of OBP-601(Censavudine) in 94 institutions in 17 countriesSources

US patent granted for OBP-301 (US Patent No. 8,163,892)Sources

U.S. Patent 8,163,892 of OBP-301 (Telomelysin) was issued.Sources

Signed a joint research agreement with Juntendo University using OBP-401Sources

Concluded a collaboration research agreement with Juntendo University regarding OBP-401 (TelomeScan)Sources

Signed a joint research agreement with the National Hospital Organization Kure Medical Center / China Cancer Center using OBP-401Sources

Concluded a collaboration research agreement with National Hospital Organization Kure Medical Center and Chugoku Cancer Center regarding OBP-401 (TelomeScan)Sources

Obtained a grant from JST (Japan Science and Technology Agency) as Feasibility Study (FS) Stage, Seeds Validation Type in Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-Step) for OBP-401 (TelomeScan)Sources

Concluded a worldwide exclusive license agreement with Geron Corporation for licensing patents concerning human telomerase specific reverse transcriptase (hTERT) promoter for diagnostic use in cancerSources

Obtained a grant from NEDO for OBP-801 as Innovation Promotion Program of Venture Support for fiscal 2010Sources

OBP-801 was selected for the NEDO (New Energy and Industrial Technology Development Organization) Innovation Practicalization Venture Support Project.Sources

Oncolys BioPharma was listed on the Tokyo Stock Exchange Mothers.Sources

Listed on the Tokyo Stock Exchange Mothers market.Sources

OBP-801 was selected for the NEDO Innovation Practicalization Venture Support Project.Sources

Started Phase 1/2 clinical trial in the Korea & Taiwan for TelomelysinSources

Phase 1/2 clinical trials of OBP-301 were initiated in Taiwan.Sources

Submitted an IND (Investigational New Drug) application for OBP-801 to the U.S. Food and Drug Administration (FDA).Sources

Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-801Sources

Started Phase 1 clinical trial in the U.S. for OBP-801Sources

Started research and development of OBP-702 & OBP-405Sources

Phase 1 clinical trials of the epigenetic cancer therapeutic OBP-801 were started in the United States.Sources

Commercial sales of the cancer diagnostic test OBP-401 to Deciphera Pharmaceuticals, LLC (U.S.), a company specializing in kinase inhibitor development, commenced.Sources

Initiated research and development of next-generation oncolytic viruses OBP-702 and OBP-405.Sources

It was decided that the cancer diagnostic test OBP-401 would be used to validate efficacy in Deciphera Pharmaceuticals, LLC (U.S.)'s anticancer drug development.Sources

Completed the maximum tolerated dose administration of OBP-301 Phase 1/2 clinical trials in Taiwan and South Korea.Sources

Concluded a joint research agreement with Graduate School of Medicine, Nagoya University, for Telomelysin (OBP-301) combined with checkpoint inhibitor.Sources

Concluded an investigator-initiated trial agreement with National Cancer Center Hospital East for Telomelysin (OBP-301) combined with other therapies.Sources

Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgery.Sources

Submitted a protocol of Telomelysin (OBP-301) to the Food and Drug Administration (FDA), for a Phase 2 clinical trial in the United States, for melanoma.Sources

Entered into a physician-led clinical trial agreement to evaluate the efficacy of combining the tumor-lysing virus OBP-301 with other therapies in patients with progressive or metastatic solid tumors, with Dr. Toshihiko Doi's research group from the Advanced Medical Care Department of the National Cancer Center Hospital East.Sources

Completed the protocol submission for the US Phase 2 clinical trial of OBP-301 targeting malignant melanoma.Sources

Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgerySources

Submitted a protocol of Telomelysin (OBP-301) to the Food and Drug Administration (FDA), for a Phase 2 clinical trial in the United States, for melanomaSources

Established Oncolys USA Inc.Sources

Established the wholly-owned subsidiary Oncolys USA Inc. in Delaware, USA, to accelerate licensing agreements for pharmaceuticals and diagnostic reagents and research and development activities, and commenced operations in New Jersey.Sources

Submitted CTN for Phase 1 clinical trial in combination with radiotherapy for esophageal cancer to PMDA (Pharmaceuticals and Medical Devices Agency).Sources

Entered into a capital partnership agreement with US biotech venture Precision Virologics Inc., specializing in emerging infectious disease vaccine research and development.Sources

Submitted CTN for Phase 1 clinical trial in combination with radiotherapy for esophageal cancer to PMDA(Pharmaceuticals and Medical Devices Agency)Sources

Initiated Phase 1 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan.Sources

Patent registration of OBP-1101 in the United States.Sources

Initiated dosing for the Phase 1 trial of OBP-301 combined with radiation therapy in esophageal cancer (Japan).Sources

Initiated dosing for the Phase 2 trial of OBP-301 targeting melanoma (United States).Sources

Initiated Phase 1 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in JapanSources

Patent granted for OBP-1101 in China.Sources

Patent granted for the substance patent of OBP-601 in Europe.Sources

Entered into a joint research agreement with Juntendo University for circulating tumor cells (CTC) toward the commercialization of OBP-401/OBP-1101.Sources

Started investigator-initiated clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab, an anti-PD-1 antibody in Japan.Sources

Initiated dosing for the Phase 1 trial primarily targeting esophageal cancer, combining OBP-301 with the anti-PD-1 antibody pembrolizumab (Japan).Sources

Started investigator-initiated clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab, an anti-PD-1 antibody in JapanSources

Patent granted for OBP-1101 in Europe.Sources

Entered into a worldwide license agreement with UK-based Stabilitech for the virus preservation stabilizer patent.Sources

Received "SAKIGAKE designation" on OBP-301 (Telomelysin) by Ministry of Health, Labour and Welfare.Sources

OBP-301 designated as a subject item under the Ministry of Health, Labour and Welfare's 'Accelerated Review Designation' system.Sources

Entered into an exclusive license and option agreement for OBP-301 in Japan and Taiwan with Chugai Pharmaceutical Co., Ltd.Sources

Received "SAKIGAKE designation" on OBP-301 (Telomelysin) by Ministry of Health, Labour and WelfareSources

Initiated dosing for the Phase 2 trial primarily focused on gastric cancer and others, combining OBP-301 with anti-PD-1 antibody pembrolizumab (United States).Sources

Chugai Pharmaceutical achieved the first milestone under the OBP-301 license agreement.Sources

Initiated Phase 2 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan.Sources

Chugai Pharmaceutical initiated dosing for the Phase 2 clinical trial of OBP-301 combined with radiation therapy in esophageal cancer (Japan).Sources

Established the wholly-owned subsidiary OPA Therapeutics Inc. in California, USA.Sources

Initiated Phase 2 clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in JapanSources

Received Orphan Drug Designation from the US FDA for OBP-301 as a treatment for esophageal cancer.Sources

Concluded a worldwide Exclusive License Agreement with Transposon Therapeutics, Inc (U.S.A.) on the nucleoside reverse transcriptase inhibitor (NRTI) OBP-601 (censavudine).Sources

The U.S. Food and Drug Administration designated OBP-301 as an orphan drug.Sources

Transposon Therapeutics, Inc. (USA) entered into a worldwide exclusive license agreement for OBP-601.Sources

Signed a patent assignment agreement with Kagoshima University and began development of a novel coronavirus treatment.Sources

Received Orphan Drug Designation from the US FDA for OBP-301 as a treatment for esophageal cancerSources

Concluded a worldwide Exclusive License Agreement with Transposon Therapeutics, Inc (U.S.A.) on the nucleoside reverse transcriptase inhibitor (NRTI) OBP-601 (censavudine)Sources

Transposon achieved the first milestone under the OBP-601 license agreement.Sources

Been selected "suratanodeturev" for OBP-301 (Telomelysin) by International Nonproprietary Names (INN) Expert Committee of the WHO.Sources

The World Health Organization (WHO) designated the international nonproprietary name of OBP-301 as suratadenoturev.Sources

Been selected “suratanodeturev” for OBP-301 (Telomelysin) by International Nonproprietary Names (INN) Expert Committee of the WHOSources

Transposon commenced dosing in a Phase 2 clinical trial (USA) for OBP-601 targeting progressive supranuclear palsy (PSP).Sources

Transposon began dosing in a Phase 2a clinical trial (USA) for OBP-601 targeting amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).Sources

Listed on the Tokyo Stock Exchange Growth Market.Sources

Transposon completed enrollment of patients in the Phase 2 clinical trial for OBP-601 targeting progressive supranuclear palsy (PSP).Sources

Achieved the last patient enrollment in Phase 2 pivotal clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in Japan.Sources

Completed final enrollment in the Phase 2 clinical trial of OBP-301 combined with radiation for esophageal cancer.Sources

Achieved the last patient enrollment in Phase 2 pivotal clinical trial for OBP-301 (Telomelysin) in combination with radiotherapy for esophageal cancer in JapanSources

Made an announcement of the results from an investigator-initiated phase 2 clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab in advanced gastric and gastroesophageal junction (GEA) adenocarcinoma at ASCO 2023.Sources

Presented results of the Phase 2 clinical trial of OBP-301 combined with pembrolizumab for gastric cancer at ASCO 2023.Sources

Made an announcement of the results from an investigator-initiated phase 2 clinical trial for OBP-301 (Telomelysin) in combination with pembrolizumab in advanced gastric and gastroesophageal junction (GEA) adenocarcinoma at ASCO 2023Sources

Signed a sales partnership agreement in Japan for OBP-301 with Fujifilm Toyama Chemical.Sources

OBP-601 was designated for Fast Track status for progressive supranuclear palsy (PSP).Sources

Initiated a pre-IND comprehensive evaluation consultation for OBP-301.Sources

Obtained a manufacturing and sales license for regenerative medicine products.Sources

OBP-301 was designated as a regenerative medicine product for rare diseases.Sources

Filed a manufacturing and sales approval application for OBP-301.Sources

Obtained standard approval for manufacturing and sales of the oncolytic virus telomelysin injection.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information4010401053237
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
オンコリスバイオファーマ株式会社
Trade name (kana)
オンコリスバイオファーマ
Name in English
Corporation type
301
Address
〒105-0001 東京都港区虎ノ門4丁目1番28号
Postal code
1050001
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-17
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
1744507
METI gBizINFO4010401053237
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4010401053237
Trade name
オンコリスバイオファーマ株式会社
Trade name (kana)
オンコリスバイオファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区虎ノ門4丁目1番28号
Postal code
1050001
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
虎ノ門4丁目1番28号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  浦田 泰生
Capital
4366132000
Employees
38
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-04-17
Key information
4010401053237
§09

Sources & updates

SOURCES
↑